Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD—A Systematic Review

Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of disease ranging from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) and fibrosis. “Obese/Metabolic NAFLD” is closely associated with obesity and insulin resistance and therefore predisposes to type 2 diabetes and cardiovascular disease. NAFLD can also be caused by common genetic variants, the patatin-like phospholipase domain-containing 3 (PNPLA3) or the transmembrane 6 superfamily member 2 (TM6SF2). Since NAFL, irrespective of its cause, can progress to NASH and liver fibrosis, its definition is of interest. We reviewed the literature to identify data on definition of normal liver fat using liver histology and different imaging tools, and analyzed whether NAFLD caused by the gene variants is associated with insulin resistance. Histologically, normal liver fat content in liver biopsies is most commonly defined as macroscopic steatosis in less than 5% of hepatocytes. In the population-based Dallas Heart Study, the upper 95th percentile of liver fat measured by proton magnetic spectroscopy (1H-MRS) in healthy subjects was 5.6%, which corresponds to approximately 15% histological liver fat. When measured by magnetic resonance imaging (MRI)-based techniques such as the proton density fat fraction (PDFF), 5% macroscopic steatosis corresponds to a PDFF of 6% to 6.4%. In contrast to “Obese/metabolic NAFLD”, NAFLD caused by genetic variants is not associated with insulin resistance. This implies that NAFLD is heterogeneous and that “Obese/Metabolic NAFLD” but not NAFLD due to the PNPLA3 or TM6SF2 genetic variants predisposes to type 2 diabetes and cardiovascular disease.

[1]  D. Booth,et al.  Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes , 2016, Hepatology.

[2]  M. Orešič,et al.  Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .

[3]  L. Perrone,et al.  TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL‐cholesterol and increased liver injury in obese children , 2016, Pediatric obesity.

[4]  Jonathan C. Cohen,et al.  Inactivation of Tm6sf2, a Gene Defective in Fatty Liver Disease, Impairs Lipidation but Not Secretion of Very Low Density Lipoproteins* , 2016, The Journal of Biological Chemistry.

[5]  Hongyu Zhao,et al.  Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study , 2016, Hepatology.

[6]  European Association for the Study of the Liver,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.

[7]  S. Kong,et al.  I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[8]  S. Sookoian,et al.  The dual and opposite role of the TM6SF2‐rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: A meta‐analysis , 2015, Hepatology.

[9]  P. Calder,et al.  Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. , 2015, Journal of hepatology.

[10]  J. Hardies,et al.  Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[11]  G. Musso,et al.  PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease , 2015, Hepatology.

[12]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[13]  Liyong Pu,et al.  PNPLA3 polymorphisms (rs738409) and non‐alcoholic fatty liver disease risk and related phenotypes: a meta‐analysis , 2015, Journal of gastroenterology and hepatology.

[14]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[15]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[16]  Shasha Zhang,et al.  Association Between Patatin-Like Phospholipase Domain Containing 3 Gene (PNPLA3) Polymorphisms and Nonalcoholic Fatty Liver Disease: A HuGE Review and Meta-Analysis , 2015, Scientific Reports.

[17]  M. Orho-Melander,et al.  Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2. , 2015, Journal of hepatology.

[18]  S. Sookoian,et al.  Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity , 2015, Hepatology.

[19]  Ningning Wang,et al.  The rs738409 (I148M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis , 2015, Journal of Lipid Research.

[20]  H. Yki-Järvinen Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.

[21]  A. Di Costanzo,et al.  Non-alcoholic fatty liver disease, metabolic syndrome and patatin-like phospholipase domain-containing protein3 gene variants. , 2014, European journal of internal medicine.

[22]  A. Hamsten,et al.  TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content , 2014, Proceedings of the National Academy of Sciences.

[23]  Gianluca Bontempi,et al.  Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data , 2014, Hepatology.

[24]  Aijaz Ahmed,et al.  Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. , 2014, World journal of hepatology.

[25]  He Zhang,et al.  Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk , 2014, Nature Genetics.

[26]  J. Browning,et al.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. , 2014, Gastroenterology.

[27]  Anne Tybjærg-Hansen,et al.  Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.

[28]  Rohit Loomba,et al.  Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials , 2013, Hepatology.

[29]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[30]  M. Taskinen,et al.  A gene variant of PNPLA3, but not of APOC3, is associated with histological parameters of NAFLD in an obese population , 2013, Obesity.

[31]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[32]  R. Idilman,et al.  Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy. , 2013, Radiology.

[33]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[34]  A. Gamst,et al.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. , 2013, Radiology.

[35]  D. Brenner,et al.  Association between novel MRI‐estimated pancreatic fat and liver histology‐determined steatosis and fibrosis in non‐alcoholic fatty liver disease , 2013, Alimentary pharmacology & therapeutics.

[36]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[37]  D. Brenner,et al.  Correlation between liver histology and novel magnetic resonance imaging in adult patients with non‐alcoholic fatty liver disease – MRI accurately quantifies hepatic steatosis in NAFLD , 2012, Alimentary pharmacology & therapeutics.

[38]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[39]  Sarah A. Scott,et al.  Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. , 2012, Cell metabolism.

[40]  Meng-Su Zeng,et al.  Standardized Ultrasound Hepatic/Renal Ratio and Hepatic Attenuation Rate to Quantify Liver Fat Content: An Improvement Method , 2011, Obesity.

[41]  Shyi-Jang Shin,et al.  The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[42]  A. Gamst,et al.  Reproducibility of MRI‐determined proton density fat fraction across two different MR scanner platforms , 2011, Journal of magnetic resonance imaging : JMRI.

[43]  Eliseo Guallar,et al.  Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta‐analysis , 2011, Hepatology.

[44]  Jonathan C. Cohen,et al.  Expression and Characterization of a PNPLA3 Protein Isoform (I148M) Associated with Nonalcoholic Fatty Liver Disease* , 2011, The Journal of Biological Chemistry.

[45]  S. Sookoian,et al.  Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease , 2011, Hepatology.

[46]  Mei-Hwei Chang,et al.  A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. , 2011, The Journal of pediatrics.

[47]  K. Vigen,et al.  T1 independent, T2* corrected chemical shift based fat–water separation with multi‐peak fat spectral modeling is an accurate and precise measure of hepatic steatosis , 2011, Journal of magnetic resonance imaging : JMRI.

[48]  B. Neuschwander‐Tetri,et al.  Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings , 2011, Hepatology.

[49]  Scott B Reeder,et al.  Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. , 2011, Radiology.

[50]  Nicholette D. Palmer,et al.  Association of PNPLA3 with non‐alcoholic fatty liver disease in a minority cohort: the Insulin Resistance Atherosclerosis Family Study , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[51]  E. Brunt,et al.  Histopathology of nonalcoholic fatty liver disease. , 2010, World journal of gastroenterology.

[52]  A. Alisi,et al.  I148M patatin‐like phospholipase domain‐containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease , 2010, Hepatology.

[53]  B. Neuschwander‐Tetri Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites , 2010, Hepatology.

[54]  V. M. Cambuli,et al.  The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. , 2010, Journal of hepatology.

[55]  J. Stoker,et al.  The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis , 2010, European Radiology.

[56]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[57]  E. Bugianesi,et al.  Homozygosity for the patatin‐like phospholipase‐3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease , 2010, Hepatology.

[58]  Nick V. Grishin,et al.  A Sequence Variation (I148M) in PNPLA3 Associated with Nonalcoholic Fatty Liver Disease Disrupts Triglyceride Hydrolysis , 2009, The Journal of Biological Chemistry.

[59]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[60]  F. Schick,et al.  Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. , 2009, Journal of hepatology.

[61]  F. Schick,et al.  Dissociation Between Fatty Liver and Insulin Resistance in Humans Carrying a Variant of the Patatin-Like Phospholipase 3 Gene , 2009, Diabetes.

[62]  Beverley Balkau,et al.  Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population , 2009, Hepatology.

[63]  M. Ridderstråle,et al.  A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans , 2009, Diabetologia.

[64]  C. Sirlin,et al.  Fatty liver disease: MR imaging techniques for the detection and quantification of liver steatosis. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.

[65]  D. Chianese,et al.  Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? , 2008, Journal of Translational Medicine.

[66]  Azmat Ali,et al.  Magnetic resonance imaging and spectroscopy for monitoring liver steatosis , 2008, Journal of magnetic resonance imaging : JMRI.

[67]  Alexander Pertsemlidis,et al.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease , 2008, Nature Genetics.

[68]  A. Kotronen,et al.  Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes. , 2008, Gastroenterology.

[69]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[70]  A. Kotronen,et al.  Effect of liver fat on insulin clearance. , 2007, American journal of physiology. Endocrinology and metabolism.

[71]  K. Pietiläinen,et al.  Liver fat in the metabolic syndrome. , 2007, The Journal of clinical endocrinology and metabolism.

[72]  Amalia Gastaldelli,et al.  Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. , 2007, Gastroenterology.

[73]  S. Curley,et al.  Comparison of CT methods for determining the fat content of the liver. , 2007, AJR. American journal of roentgenology.

[74]  Irene M Stratton,et al.  Comparison of 11 human insulin assays: implications for clinical investigation and research. , 2007, Clinical chemistry.

[75]  Claudio Cobelli,et al.  Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men , 2006, Proceedings of the National Academy of Sciences.

[76]  Sang Won Lee,et al.  Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. , 2006, Radiology.

[77]  H. Hussain,et al.  Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. , 2005, Radiology.

[78]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[79]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[80]  S. Grundy,et al.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.

[81]  H. Greene,et al.  Fatty liver: Biochemical and clinical considerations , 1975, The American Journal of Digestive Diseases.

[82]  C. Mottin,et al.  The Role of Ultrasound in the Diagnosis of Hepatic Steatosis in Morbidly Obese Patients , 2004, Obesity surgery.

[83]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[84]  C. Ryan,et al.  One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[85]  A. Häkkinen,et al.  Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. , 2002, The Journal of clinical endocrinology and metabolism.

[86]  M. Fishbein,et al.  Rapid MRI using a modified Dixon technique: a non-invasive and effective method for detection and monitoring of fatty metamorphosis of the liver , 2001, Pediatric Radiology.

[87]  F. Schick,et al.  Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.

[88]  P. Schmalbrock,et al.  Introduction of fast MR imaging in the assessment of hepatic steatosis. , 1995, Magnetic resonance imaging.

[89]  N. Rofsky,et al.  Comparison between in-phase and opposed-phase T1-weighted breath-hold FLASH sequences for hepatic imaging. , 1996, Journal of computer assisted tomography.

[90]  C. Thomsen,et al.  Quantification of liver fat using magnetic resonance spectroscopy. , 1994, Magnetic resonance imaging.

[91]  C. Tiribelli,et al.  Fatty Infiltration of the Liver: Quantification by 1H Localized Magnetic Resonance Spectroscopy and Comparison with Computed Tomography , 1993, Investigative radiology.

[92]  A. Joseph,et al.  Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. , 1991, Clinical radiology.

[93]  B. Goldberg,et al.  Sonography of diffuse benign liver disease: accuracy of pattern recognition and grading. , 1986, AJR. American journal of roentgenology.

[94]  J. Maxwell,et al.  Ultrasound scanning in the detection of hepatic fibrosis and steatosis. , 1986, British medical journal.

[95]  W. T. Dixon Simple proton spectroscopic imaging. , 1984, Radiology.

[96]  G. Bydder,et al.  Computed tomography attenuation values in fatty liver. , 1981, The Journal of computed tomography.

[97]  L Axel,et al.  Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. , 1980, Radiology.

[98]  K. Dewbury,et al.  The accuracy of ultrasound in the detection of fatty infiltration of the liver. , 1980, The British journal of radiology.

[99]  K. Dewbury,et al.  Ultrasound in the detection of chronic liver disease (the "bright liver"). , 1979, The British journal of radiology.

[100]  H. Donhoffer Quantitative estimation of lipids in needle biopsy sized specimens of cadaver liver. , 1974, Acta medica Academiae Scientiarum Hungaricae.

[101]  A. Lundquist,et al.  Lipid composition of human liver biopsy specimens. , 2009, Acta medica Scandinavica.